UPDATE: Raymond James On Sol-Gel Price Target Trim: Positive On Recent FDA Approval Of TWYNEO Which Prompted $3.5M Upfront Payment From Galderma; Believes Co. To Be 'Relatively Derisked With A Solid Risk/Reward Profile' With Consistent Cash Inflows